Bio-techne (TECH)

Executive Summary

Bio-Techne (NASDAQ: TECH) is a global life sciences company providing essential reagents, instruments, and diagnostics for research and clinical applications. Operating through Protein Sciences and Diagnostics & Genomics segments, its portfolio includes market-leading brands such as R&D Systems, Novus Biologicals, ProteinSimple, and Exosome Diagnostics. The company serves academic, government, pharmaceutical, and clinical markets worldwide. Despite near-term headwinds from biotech funding volatility and instrument purchasing delays, Bio-Techne has demonstrated resilience due to the essential nature of its consumables and a growing diagnostics business. The company's focus on high-growth areas like oncology and exosome-based liquid biopsy positions it for long-term demand tailwinds.

Upcoming Catalysts (preview)

• Q2 2026Launch of next-generation ProteinSimple platforms (e.g., Simple Western upgrades)75% success
• 2026Expansion of ExoDx Prostate test reimbursement coverage and clinical adoption65% success
• H2 2026Recovery in biopharma funding driving instrument and reagent sales improvement60% success